RA
CALA

Royce & Associates’s Calithera Biosciences, Inc CALA Stock Holding History

Royce & Associates’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-38
Closed -$5K – 1275
2018
Q1 		$5K Buy
38
+5
+15% +$780 ﹤0.01% 1243
2017
Q4 		$5K Buy
+33
New +$8.45K ﹤0.01% 1238

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Royce & Associates's CALA Position: Q2 2018 in Review

Royce & Associates sold out of Calithera Biosciences, Inc (CALA) in Q2 2018, closing a stake of 38 shares — an estimated $5K sold.

Royce & Associates first reported a position in CALA in Q4 2017 and held it in 2 quarters. The position peaked at $5K in Q1 2018. 90 funds tracked by Wall St. Rank hold CALA as of Q2 2018.

  • Royce & Associates reported no remaining Calithera Biosciences, Inc position as of Q2 2018 after selling out during the quarter.
  • Royce & Associates sold 38 Calithera Biosciences, Inc shares in Q2 2018, an estimated $5K.
  • Royce & Associates first reported a position in Calithera Biosciences, Inc in Q4 2017 and held it in 2 quarters.
  • Royce & Associates's Calithera Biosciences, Inc position peaked at $5K in Q1 2018.
  • 90 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2018.

Based on Royce & Associates's 13F filing for Q2 2018, filed 9 Aug 2018.